Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neutropenia: full-pipeline trial registry
6 of 14 indexed Neutropenia trials are currently recruiting.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 6 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Neutropenia: 14 US clinical trials tracked, 6 recruiting.
Neutropenia is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition neutropenia
OPEN 6 | RECR 43% | LATE 5 | EARLY 7 | RANK #1230 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Neutropenia lists 6 open slots (43% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neutropenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neutropenia is recruiting below its size-band peers.
6 of 14 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neutropenia research.
National Cancer Institute (NCI) accounts for 3 of 14 trials (21.4%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Neutropenia trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 13 trials that report a genuine target (sentinel values excluded). 10 of those (76.9%) plan for fewer than 100 participants.
-
Neutropenia research is mostly interventional.
12 interventional and 2 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
X4 Pharmaceuticals
NCT06056297
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
West Virginia University
NCT05537896
Luspatercept for Clonal Cytopenias of Uncertain Significance
Weill Medical College of Cornell University
NCT06788691
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Tufts Medical Center
NCT05626530
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00967785
Serial Blood Count Study
University of Washington
NCT07066085
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy
Alliance for Clinical Trials in Oncology
NCT00048971
Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
Carelon Research
NCT00627393
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
National Cancer Institute (NCI)
NCT00001338
SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia
SWOG Cancer Research Network
NCT00002665
Effect of Body Mass on Filgrastim Pharmacokinetics
Aaron Cumpston, PharmD, BCOP
NCT01719432
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001646
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00002759
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
National Cancer Institute (NCI)
NCT00020371
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neutropenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neutropenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neutropenia page
14 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Neutropenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neutropenia trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neutropenia condition card totals 14 registered trials; most-linked intervention polymorphic microsatellite marker analysis; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.